Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

Y0000425

Lamivudine

European Pharmacopoeia (EP) Reference Standard

Synonyma:

2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C8H11N3O3S
Číslo CAS:
134678-17-4
Molekulová hmotnost:
229.26
MDL number:
MFCD00869739
UNSPSC Code:
41116107
PubChem Substance ID:
329830949
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

lamivudine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

InChI key

JTEGQNOMFQHVDC-NKWVEPMBSA-N

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Související kategorie

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lamivudine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Č. produktu
Popis
Stanovení ceny

1356858

Lamivudine Resolution Mixture B, United States Pharmacopeia (USP) Reference Standard

1356836

Lamivudine, United States Pharmacopeia (USP) Reference Standard

Y0000426

Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard

Y0000518

Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard

1356847

Lamivudine Resolution Mixture A, United States Pharmacopeia (USP) Reference Standard

1356869

Lamivudine Resolution Mixture C, United States Pharmacopeia (USP) Reference Standard

BP802

Lamivudine, British Pharmacopoeia (BP) Reference Standard

BP857

Lamivudine impurity standard, British Pharmacopoeia (BP) Reference Standard

BP850

Zidovudine and Lamivudine impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR8938

Lamivudine (R)-Sulfoxide, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361

pcodes

P280

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Stephen Weller et al.
Journal of acquired immune deficiency syndromes (1999), 66(4), 393-398 (2014-05-07)
The integrase inhibitor dolutegravir and nucleoside analogues abacavir and lamivudine are once-daily treatment options for HIV. This study (NCT01622790) evaluated, first, the bioequivalence (BE) of a fixed-dose combination (FDC) tablet containing dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300
Youwen Tan et al.
PloS one, 7(3), e32789-e32789 (2012-04-06)
Several recent reports have demonstrated that tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) motif mutations can naturally occur in chronic HBV patients without antiviral treatment such as lamivudine therapy. This paper aims to assess the overall spontaneous incidence and
Zhongjie Shi et al.
Obstetrics and gynecology, 116(1), 147-159 (2010-06-23)
To evaluate efficacy of lamivudine in reducing in utero transmission of hepatitis B virus (HBV). A database was constructed from Medline, EMBASE, Cochrane Library, National Science Digital Library, China Biological Medicine Database, and through contact with experts in the field
Kuo-Chih Tseng et al.
Antiviral therapy, 19(8), 755-764 (2014-03-04)
It is still inconclusive whether chronic hepatitis B (CHB) patients with persistently normal alanine aminotransferase (PNALT) should receive nucleoside/nucleotide analogues. This study is to evaluate the efficacy of entecavir in improving liver histology in CHB patients with PNALT. In this
N B Bhatt et al.
Antimicrobial agents and chemotherapy, 58(6), 3182-3190 (2014-03-26)
This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.